Fuso Pharmaceutical Industries,Ltd. (TYO:4538)
Japan · Delayed Price · Currency is JPY 2,168.00
+28.00 (1.31%)
Jul 14, 2026, 3:30 PM JST
TYO:4538 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 |
Operating Revenue | 62,307 | 60,562 | 55,406 | 48,612 | 44,358 |
Other Revenue | - | 1 | 1 | - | - |
| 62,307 | 60,563 | 55,407 | 48,612 | 44,358 | |
Revenue Growth (YoY) | 2.88% | 9.31% | 13.98% | 9.59% | -6.55% |
Cost of Revenue | 46,311 | 44,030 | 41,567 | 33,296 | 32,164 |
Gross Profit | 15,996 | 16,533 | 13,840 | 15,316 | 12,194 |
Selling, General & Admin | 13,355 | 12,401 | 11,874 | 9,606 | 9,731 |
Research & Development | - | - | - | 1,673 | 1,739 |
Operating Expenses | 13,355 | 12,401 | 11,874 | 11,499 | 11,713 |
Operating Income | 2,641 | 4,132 | 1,966 | 3,817 | 481 |
Interest Expense | -328 | -161 | -171 | -263 | -262 |
Interest & Investment Income | 142 | 107 | 96 | 267 | 56 |
Other Non Operating Income (Expenses) | -192 | -381 | -104 | -57 | -201 |
EBT Excluding Unusual Items | 2,263 | 3,697 | 1,787 | 3,764 | 74 |
Gain (Loss) on Sale of Investments | 91 | - | -80 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 2,841 | - |
Asset Writedown | - | -7 | -20 | -369 | -67 |
Pretax Income | 2,437 | 3,774 | 1,767 | 6,236 | 7 |
Income Tax Expense | 426 | 994 | 390 | 1,365 | -365 |
Net Income | 2,011 | 2,780 | 1,377 | 4,871 | 372 |
Net Income to Common | 2,011 | 2,780 | 1,377 | 4,871 | 372 |
Net Income Growth | -27.66% | 101.89% | -71.73% | 1209.41% | -67.48% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 |
Shares Change (YoY) | -0.05% | -0.79% | -4.89% | -0.02% | -0.03% |
EPS (Basic) | 235.52 | 325.43 | 159.92 | 538.01 | 41.08 |
EPS (Diluted) | 235.52 | 325.43 | 159.92 | 538.01 | 41.08 |
EPS Growth | -27.63% | 103.50% | -70.28% | 1209.63% | -67.47% |
Free Cash Flow | -7,490 | - | - | 1,330 | -322 |
Free Cash Flow Per Share | -877.19 | - | - | 146.90 | -35.56 |
Dividend Per Share | 90.000 | 82.000 | 70.000 | 60.000 | 60.000 |
Dividend Growth | 9.76% | 17.14% | 16.67% | - | - |
Gross Margin | 25.67% | 27.30% | 24.98% | 31.51% | 27.49% |
Operating Margin | 4.24% | 6.82% | 3.55% | 7.85% | 1.08% |
Profit Margin | 3.23% | 4.59% | 2.48% | 10.02% | 0.84% |
Free Cash Flow Margin | -12.02% | - | - | 2.74% | -0.73% |
EBITDA | 5,259 | - | - | 5,567 | 2,369 |
EBITDA Margin | 8.44% | - | - | 11.45% | 5.34% |
D&A For EBITDA | 2,618 | - | - | 1,750 | 1,888 |
EBIT | 2,641 | 4,132 | 1,966 | 3,817 | 481 |
EBIT Margin | 4.24% | 6.82% | 3.55% | 7.85% | 1.08% |
Effective Tax Rate | 17.48% | 26.34% | 22.07% | 21.89% | - |
Revenue as Reported | 62,307 | 60,563 | 55,407 | - | - |